Uncategorized

Lupus & Life: Diet, Nutrition, and the Microbiome 

|

How can diet and nutrition affect lupus? What foods could potentially be “good” for lupus? What is the gut microbiome – and how is lupus impacted by it?   Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, dug into these questions and more by convening leading healthcare professionals and people living with lupus for the second in our webinar series, “Lupus & Life: Science, Support, and Self-Care.”  Moderated by Caroline Donovan, MPH, Senior Director, Patient Engagement & Education, the webinar explored the impact of diet … Lupus & Life: Diet, Nutrition, and the Microbiome 

Lupus Research Alliance Welcomes U.S. FDA Breakthrough Therapy Designation for Enpatoran for the Treatment of Lupus with Skin Manifestations

|

The Lupus Research Alliance welcomes the decision by the U.S. Food and Drug Administration (FDA) to grant Breakthrough Therapy designation to enpatoran in clinical development by EMD Serono, the Healthcare business of Merck KGaA, Darmstadt, Germany, in the U.S. and Canada, for the treatment of lupus with active cutaneous manifestations. The FDA grants this designation to expedite the review of drugs for serious conditions that may demonstrate substantial improvement over available … Lupus Research Alliance Welcomes U.S. FDA Breakthrough Therapy Designation for Enpatoran for the Treatment of Lupus with Skin Manifestations

Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, is encouraged by positive late-breaking Phase 2 data with nipocalimab, an investigational drug in development by Johnson & Johnson showing significantly reduced disease activity in adults with moderate-to-severe systemic lupus erythematosus (SLE). These data, part of the JASMINE study, were presented today at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress.  In the JASMINE study, at 52 weeks, nipocalimab plus standard of … Late-Breaking Data at EULAR Shows Investigational Drug Nipocalimab Significantly Reduces Disease Activity in Lupus 

Positive Results of Phase 3 Dapirolizumab Pegol Trial in Systemic Lupus Erythematosus Shown in Published Paper

|

Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, welcomes additional positive results from the Phase 3 PHOENYCS GO study showing that combined with standard care, investigational dapirolizumab pegol (DZP) in development by UCB and Biogen Inc. significantly improved disease activity in patients with moderate-to-severe active systemic lupus erythematosus (SLE). These data were published in The Lancet, a highly prestigious … Positive Results of Phase 3 Dapirolizumab Pegol Trial in Systemic Lupus Erythematosus Shown in Published Paper

2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

|

What if clinical trials were not a final option, but a routine part of lupus care?   That question took center stage at the 2026 Lupus Clinical Investigators Network (LuCIN) Community Meeting, where people living with lupus, researchers, clinicians, and industry leaders came together to reshape the future of treatment. LuCIN Investigators (left) and Coordinators join onsite for meaningful … 2026 LuCIN Community Meeting Focuses on Integrating Clinical Trials into Day-to-Day Clinical Care 

Saphnelo™ Approved as Self-Administered Autoinjector

|

The U.S. Food and Drug Administration just granted approval for a self-administered, once-weekly autoinjector of Saphenlo (anifrolumab), for the treatment of adult patients with systemic lupus erythematosus (SLE) on top of standard therapy.  The decision was based on TULIP-SC Phase 3 trial results, which showed a statistically significant and clinically meaningful reduction in disease activity for participants with moderate to severe … Saphnelo™ Approved as Self-Administered Autoinjector

Lupus & Life: Heart Health, Lupus, and How You Can Take Control

|

How does lupus impact heart health?  People living with systemic lupus erythematosus (SLE) face an increased risk of cardiovascular disease, with even greater risk among those with lupus nephritis. Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, convened leading rheumatologists and people living with lupus for the first in our webinar series, “Lupus & Life: Science, Support, and Self-Care,” to take a closer look at … Lupus & Life: Heart Health, Lupus, and How You Can Take Control

FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

|

The U.S. Food and Drug Administration has accepted the supplemental Biologics License Application from Genentech for Gazyva® (obinutuzumab) to treat systemic lupus erythematosus (SLE), the most common form of lupus. The acceptance is based on Phase 3 data showing that Gazyva significantly reduced disease activity and less reliance on steroids in people with SLE.   According to results published in the New England Journal of Medicine and presented at SLEuro 2026, more than 75% of people treated with Gazyva plus standard therapy achieved … FDA Accepts Application for Gazyva® (obinutuzumab) to Treat SLE

New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

|

Lupus Therapeutics, clinical affiliate of the Lupus Research Alliance, welcomes new results from the Phase 2 part of the AMETHYST Phase 2/3 study, showing that the investigational litifilimab in development by Biogen significantly reduced skin disease activity in cutaneous lupus erythematosus (CLE). These data were presented at the American Academy of Dermatology Annual Meeting on … New Phase 2 Data Showed that Litifilimab Significantly Reduced Disease Activity in Cutaneous Lupus Erythematosus 

Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

|

Living with lupus means managing physical symptoms, emotional ups and downs, and the everyday challenges that come with an autoimmune condition. While there’s no one‑size‑fits‑all approach, many people find that caring for both the mind and body can make a meaningful difference.  To help support the lupus community, Lupus Therapeutics, the clinical affiliate of the Lupus … Stay Well with Lupus: Tips for Meditation, Movement, and Stress Management 

New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

|

A new Phase 3 study published in the New England Journal of Medicine found that Gazyva® (obinutuzumab) significantly reduced disease activity and lowered steroid use in people with systemic lupus erythematosus (SLE), the most common form of lupus. The results were also presented today at the 15th European Lupus Society meeting, SLEuro 2026.  More than 75% of people treated with Gazyva plus standard therapy achieved at least … New Phase 3 Study Shows that Gazyva® (obinutuzumab) Significantly Reduces Lupus Disease Activity in SLE

Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care

|

People living with lupus can have early access to innovative therapies alongside personalized support from a broader care team. How? Through participation in clinical trials.  Historically, clinical trial participation for lupus was discussed only after standard treatments failed the patient. Now, Lupus Therapeutics, the clinical affiliate of the Lupus Research Alliance, is working to make … Turning the Tide in Lupus Treatment: Clinical Trials as Standard of Care